CFTR 100+ Panel

CFTR 100+ Panel: Comprehensive Cystic Fibrosis Genotyping

Cystic fibrosis (CF) is one of the most common life-threatening inherited disorders, with approximately 1 in 25 individuals carrying a mutation in the CFTR gene. Despite this prevalence, many traditional genotyping assays fall short of current guideline recommendations, often targeting a limited set of variants that are not representative across diverse populations.

The CFTR 100+ Panel addresses these limitations by offering a comprehensive, high-throughput solution for CFTR variant detection. Designed to align with current guidelines and real-world research needs, the panel enables accurate and inclusive genotyping in a single, streamlined assay.

Extensive and Inclusive Variant Coverage

The panel includes all 100 CFTR variants recommended by the American College of Medical Genetics and Genomics (ACMG), supplemented with additional variants of known relevance. This expanded content ensures broader population coverage and supports more representative genetic analysis across ethnically diverse cohorts.

High Performance and Reliability

Validated through multi-site studies, the CFTR 100+ Panel demonstrates high accuracy, sensitivity, and specificity. Its robust design ensures reproducible performance across instruments, operators, and varying laboratory conditions, making it suitable for routine use in demanding research environments.

Efficient, High-Throughput Workflow

Running on the MassARRAY® System with iPLEX® Pro chemistry, the panel delivers a streamlined workflow from DNA to results in as little as 8 hours. Minimal hands-on time and scalable throughput enable laboratories to process large sample volumes efficiently without compromising data quality.

Automated Analysis and Clear Reporting

Integrated software provides automated data analysis and reporting at no additional cost. This ensures clear, concise, and reliable results, supporting fast interpretation and confident decision-making in both research and laboratory settings.

Designed for Modern CF Research

By combining comprehensive variant coverage with a flexible and efficient workflow, the CFTR 100+ Panel overcomes the limitations of traditional Cystic Fibrosis genotyping assays. It enables a deeper understanding of CFTR mutation diversity and supports more accurate and inclusive genetic studies.

Conclusion

The CFTR 100+ Panel represents a next-generation approach to cystic fibrosis genotyping. With its broad coverage, validated performance, and efficient workflow, it provides laboratories with a powerful and scalable tool for advancing CF research and improving genetic insights.